U.S. markets closed

Natera, Inc. (NTRA)

NasdaqGS - NasdaqGS Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
105.98+4.83 (+4.78%)
Al cierre: 04:00PM EDT
104.26 -1.72 (-1.62%)
Fuera de horario: 07:58PM EDT

Natera, Inc.

13011 McCallen Pass
Building A Suite 100
Austin, TX 78753
United States
650 980 9190
https://www.natera.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo3,282

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Matthew Rabinowitz Ph.D.Co-Founder & Executive Chairman768.38kN/D1973
Mr. Steven Leonard ChapmanCEO & Director1.59MN/D1979
Mr. Michael B. Brophy M.B.A.Chief Financial Officer724.62kN/D1980
Mr. Daniel Rabinowitz L.L.M.Secretary & Chief Legal Officer610.61kN/D1969
Mr. John FeskoPresident & Chief Business OfficerN/DN/D1979
Mr. Jonathan Sheena M.Eng.Co-Founder & Director293.91k10.04M1973
Ms. Olesya A. Anisimova CPAChief Accounting OfficerN/DN/DN/D
Mr. Rishi KackerChief Technology OfficerN/DN/DN/D
Mr. Eric A. EvansChief Scientific OfficerN/DN/DN/D
Mr. Jerry DiffleyChief Compliance & Privacy OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Gestión corporativa

La calificación ISS Governance QuickScore de Natera, Inc. a partir del 1 de julio de 2024 es 7. Las puntuaciones principales son Auditoría: 3; Junta: 8; Derechos del accionista: 8; Compensación: 7.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.